2nd Annual Pharmaceutical Reimbursement & Market Access Conference

Recognizing the Impact of US Healthcare Reform on the Pharmaceutical Industry, Securing Adequate Coverage & Reimbursement in an Uncertain Environment, to Further Commercialize and Extend Market Reach at Home & Abroad

December 6-7, 2010
Philadelphia, PA

About the Conference

The past twelve months have been full of confusion and concern for executives handling the coverage, reimbursement and market penetration of their therapies. Potential changes to healthcare structures in the US, the impact of which are still unknown, coupled with continued pressure from payers throughout the world to reduce prices and offer greater value has pushed many companies to the brink. Risk-based approaches to coverage and reimbursement, and the increased consideration of programs such as performance based payments are only adding to the considerable strain being felt by the pharmaceutical and biotechnology industries. Through a well balanced agenda that brings the perspectives of not only industry, but private and public payers, along with expert consultants and legal firms, this program will build upon the initial success of the Q1 productions reimbursement conference platform, providing expertise and knowledge to conference participants.

Topics to be Covered

• Understanding changes to reimbursement structures as a result of healthcare reform
  
• Recognizing new market opportunities created by greater consumer access to therapies
  
• Two, Five and Ten year projections on the impact of reform in the US
  
• Private payer perspectives on evolving reimbursement structures for pharmaceuticals
  
• Impact of enhanced influence of comparative effectiveness studies on reimbursement
  
• Creating a cohesive approach to reimbursement from R&D through to sales & marketing
  
• Methods for the compliant communication of coverage details from sales & marketing teams
  
• Enhanced influence and consideration of health technology assessments
  
• Global perspectives on reimbursement in opportunistic markets: case studies
  
• Evolving payment structures such as payment by results programs
  
• Pricing considerations in lieu of enhanced market competition and generic encroachment
  
• Utilization of health economic markers in clinical research & registries to support reimbursement
  
• Health policy considerations and perspectives on furthering pharmaceutical reimbursement
  
• Understanding CMS perspectives on rising pharmaceutical costs and securing coverage
  
• Impact of an aging population on healthcare in the US and abroad
  
• Utilization of evidence based medicine and patient reported outcomes to enhance reimbursement support
  
• Working with pharmacy benefit managers to support formulary enclusion
  
• Case study breakout sessions focusing on individual therapeutic areas such as oncology

Key Presentations to Include

Understanding Healthcare Reform & its Impact on the Pharmaceutical Industry
Daniel M. Todd, Senior Director, Health Policy
EMD Serono, Inc.

Healthcare Reform & the Impact on Private Payer Pharmaceutical Reimbursement & Contracting
Crystal Kuntz, Director, Government Policy
Astellas Pharma

Health Economics & Outcomes Research as a Foundation for Pricing & Reimbursement
Edward Kim, MD, MBA, Executive Director, Evidence-Based Medicine
Novartis Pharmaceuticals Corp.

And More...

To request the full two-day conference agenda, information on promotional pricing & registration details please contact:
Paul Hernandez, Marketing Manager
phernandez@Q1productions.com
312-602-9683